New Resources to Track the Impact of COVID-19 on HIV Prevention Research

In the midst of the global response to COVID-19, everyone and everything is affected, and HIV prevention research is no exception.

Research sponsors and networks, product developers and clinical trial sites are adapting to address how best to follow up with participants, minimize the impact on data and timelines, and ultimately protect the participants, communities and the integrity of the trial findings. Most HIV prevention trials are pausing enrollment of new participants, and constantly reviewing how best to manage follow-up of existing participants, prioritizing the safety of trial participants and the study teams.

AVAC has developed new resources to help track how COVID-19 is impacting HIV prevention research:

• Revised infographic showing COVID-19 effects on key HIV prevention trials.
• A downloadable table, Status Updates on Ongoing and Planned HIV Px Trials.
• A new page on avac.org—COVID 19 Implications on HIV Prevention Trials—features a round-up of guidance from regulatory bodies and updates by research entities.

We hope you’ll use these resources in your HIV prevention research advocacy. AVAC will continue to monitor these fast-moving changes to the field—watch this space!